Iopromide injection becomes the first FDA-approved contrast agent for visualizing known or suspected breast lesions in adult patients. The FDA has approved the iodine-based contrast agent iopromide ...
Approval marks a major milestone in reducing gadolinium exposure while maintaining diagnostic performance, aligning with clinical guidance to use the lowest effective dose MONTREAL, April 17, 2026 ...
Centargo compatible with Ultravist® (iopromide), Isovue® (iopamidol), Optiray® (ioversol), Omnipaque™ (iohexol) and now, Visipaque™ (iodixanol) Follows recent FDA clearance to expand the use of ...
LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today it has launched Gadoterate Meglumine Injection, USP, a bioequivalent and therapeutic equivalent substitute for the contrast agent ...
A retrospective study of 32 patients shows that contrast-enhanced ultrasound guidance can delineate tumors hidden within collapsed lung tissue and deliver a definitive diagnosis when bronchoscopy is ...
A new artificial-intelligence technology for heart imaging can potentially improve care for patients, allowing doctors to examine their hearts for scar tissue while eliminating the need for contrast ...
A new artificial-intelligence technology for heart imaging can improve care for patients, allowing doctors to examine their hearts for scar tissue while eliminating the need for contrast injections. A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results